HealthLinx Limited ABN 88 098 640 352 576 Swan Street Richmond VIC 3121 Telephone: +61 3 9208 4200 I Facsimile: +61 3 9208 4201 www.healthlinx.com.au China partner appointed for OvPlex�ovarian cancer diagnostic study CytogenDx confirmed as partner for Chinese market 9 September 2011, Melbourne, Australia: HealthLinx Limited (ASX:HTX) has executed research agreements with CytogenDx Co Ltd of China to begin a 350 patient academic study as the first step to launch the OvPlex� ovarian cancer diagnostic in China. The study will be conducted by Principal Investigator Dr Fei Xu of Wuxi Maternal and Children�s Hospital with the aim to validate OvPlex� in the Chinese population. It will involve the recruitment of 350 patients from the Wuxi and Shanghai districts. Upon a successful result the parties will then proceed with an SFDA approval pathway to have OvPlex� registered for sale in China. HealthLinx and CytogenDX will co-fund the study which will take 9-12 months to complete and is seen as the precursor to obtaining SFDA approvals. �China is potentially a huge market for OvPlex� so the commencement of the study is excellent news for the company and its shareholders,� said HealthLinx managing director Nick Gatsios. �CytogenDX is a highly respected healthcare company in the Chinese market working with groups to conduct clinical trials and then proceeding with SFDA approvals and distribution of products throughout China.� 2011 has been a highly successful year for HealthLinx in Asia with over-budget sales of OvPlex� in Singapore, excellent progress made with the ongoing 220 patient KFDA study in South Korea, signing a commercial distribution deal with SCL for South Korea and the pending launch of OvPlex� in other south east Asian
HTX Price at posting:
1.9¢ Sentiment: Buy Disclosure: Held
